Citizens JMP lowered the firm’s price target on Prothena (PRTA) to $78 from $80 and keeps an Outperform rating on the shares. Prothena reported Q1 financial results and provided a business update, reiterating timelines for key clinical readouts in 2025. The firm says the stock is “compelling” ahead of the Phase 3 results for birtamimab in AL amyloidosis and PRX012 in Alzheimer’s disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: